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PUEBLA, L., A. OCAN˜ A AND E. ARILLA. Histamine H1-receptors modulate somatostatin receptors coupled to the inhibition of
adenylyl cyclase in the rat frontoparietal cortex. Peptides 18(10) 1569–1576, 1997.—Since exogenous histamine has been previously
shown to increase the somatostatin (SS) receptor-effector system in the rat frontoparietal cortex and both histamine H1-receptor
agonists and SS modulate higher nervous activity and have anticonvulsive properties, it was of interest to determine the participation
of the H1-histaminergic system in this response. The intracerebroventricular (i.c.v.) administration of the specific histamine H1-receptor
agonist 2-pyridylethylamine (PEA) (10 mg) to rats 2 h before decapitation increased the number of SS receptors (599 6 40 vs 401 6
31 femtomoles/mg protein, p, 0.01) and decreased their apparent affinity for SS (0.41 6 0.03 vs 0.26 6 0.02 nM, p , 0.01) in rat
frontoparietal cortical membranes. No significant differences were seen for the basal and forskolin (FK)-stimulated adenylyl cyclase
(AC) activities in the frontoparietal cortex of PEA-treated rats when compared to the control group. In the PEA group, however, the
capacity of SS (1024 M) to inhibit basal and FK (1025 M)-stimulated AC activity in frontoparietal cortical membranes was significantly
higher than in the control group (34 6 1% vs 20 6 2%, p , 0.001). The ability of low concentrations of the stable GTP analogue
59-guanylylimidodiphosphate [Gpp(NH)p] to inhibit FK-stimulated AC activity in frontoparietal cortical membranes was similar in the
PEA-treated and control animals. These results suggest that the increased SS-mediated inhibition of AC activity in the frontoparietal
cortex of PEA-treated rats may be due to the increase of the number of SS receptors induced by PEA. Pretreatment with the H1-receptor
antagonist mepyramine (30 mg/kg, intraperitoneally (IP) prevented the PEA-induced changes in SS binding and SS-mediated inhibition
of AC activity. Mepyramine (30 mg/kg, IP) alone had no observable effect on the somatostatinergic system. The in vitro addition of
PEA or mepyramine to frontoparietal cortical membranes obtained from untreated rats did not affect the SS binding parameters.
Altogether, these results suggest that the H1-histaminergic system modulates the somatostatinergic system in the rat frontoparietal
cortex. © 1997 Elsevier Science Inc.
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SEVERAL immunocytochemical studies have demonstrated the
existence of histaminergic neurons in the brain which are con-
centrated in the tuberomammillary nucleus of the posterior
hypothalamus and which project efferent fibers to almost all
parts of the brain, including the cerebral cortex (45,63). Hista-
mine has been shown to act as a neuroregulator or neurotrans-
mitter in the mammalian central nervous system (CNS) (49,67)
and has been implicated in the regulation of higher nervous
activity (19,43) and behavioral arousal (33,64) through its in-
teraction with H1-receptors (54). Somatostatin (SS), a tetra-
decapeptide widely distributed throughout the CNS (26), regu-
lates many aspects of CNS function including arousal (17) and
higher nervous activity (26) and may act as an endogenous
anticonvulsant (35,48). In addition, it has been shown that SS
decreases cortical histamine levels (9,10). We recently demon-
strated that exogenous histamine increases the SS receptor-
effector system in the rat frontoparietal cortex (50). It is not
unreasonable to suggest, therefore, that the H1-histaminergic
system may modulate the somatostatinergic system. The fron-
toparietal cortex contains high levels of SS and H1-histaminer-
gic receptors (24,25,44,58,60,62). The SS receptors are coupled
to the adenylyl cyclase (AC) enzyme system via the guanine
nucleotide-binding inhibitory protein Gi (34,40,52,55). An H1-
histamine receptor agonist, 2-pyridylethylamine (PEA) (22,65),
and antagonist, mepyramine (22,65), were therefore used to
examine the role of the H1-histamine receptors in the regulation
of the SS receptor-effector system in rat frontoparietal cortical
membranes. Low concentrations of the stable GTP analogue
59-guanylylimidodiphosphate [Gpp(NH)p] were employed to
detect functional Gi-protein activity by inhibiting AC activity
that has been amplified by FK (61). We extended our analysis
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in order to study the possible effects of PEA and/or mepyramine
on somatostatin-like immunoreactivity (SSLI) content in the
frontoparietal cortex.
METHOD
Materials
Synthetic Tyr11-SS and SS-14 were purchased from Universal
Biologicals Ltd (Cambridge, UK); carrier-free Na125I (IMS 30,
100 mCi/ml) was purchased from the Radiochemical Center (Am-
ersham, U.K.); bacitracin, bovine serum albumin (BSA), FK,
mepyramine maleate, phenylmethylsulphonyl fluoride (PMSF),
GTP, and 3-isobutyl-1-methylxanthine (IBMX) were purchased
from Sigma (Madrid, Spain); 2-pyridylethylamine dihydrochloride
(PEA) was supplied by Smith, Kline and French. The rabbit
antibody used in the radioimmunoassay technique was purchased
from the Radiochemical Centre (Amersham, U.K.). This antiserum
was raised in rabbits against SS-14 conjugated to BSA and is
specific for SS, but since SS-14 constitutes the C-terminal portions
of both SS-25 and SS-28, the antiserum does not distinguish
between these three forms. The binding of SS-14 to this antibody
does not depend on an intact disulfide bond in the molecule as
breaking of the disulfide bond by reaction with 0.1% mercapto-
ethanol (boiling water bath, 5 min) did not change the immuno-
reactivity of the peptide. Cross-reactivity with other peptides was
less than 0.5%. Cross-reaction with several somatostatin analogues
demonstrated that neither the N-terminal glycine nor the C-termi-
nal cysteine residue is required for antibody binding, suggesting
that the antigen site is directed towards the central part of the
molecule containing the tryptophan residue.
Experimental Animals
The animals used in this study were sixty Wistar rats weighing
between 200–250 g. Rats were maintained on a 12 h light/dark
cycle (07.00–19.00) and allowed free access to food and water.
Mepyramine (5, 10, 30 or 60 mg/kg) was dissolved in 0.9% NaCl
and injected intraperitoneally (IP) as previously described (42).
PEA (2.5, 5, 10 or 20 mg/rat) was dissolved in 0.9% NaCl (11) and
injected intracerebroventricularly (i.c.v.) in a volume of 10 ml
according to the method described by Noble et al. (41). In one
experimental group, mepyramine (30 mg/kg, IP) was administered
1 h before PEA (10 mg, i.c.v.). Control animals for each experi-
mental group were injected with equivalent volumes of saline. The
animals were decapitated 2 h after injection of the drug. The brains
were rapidly removed and the frontoparietal cortex was dissected
over ice according to the method of Glowinski and Iversen (29).
Tissue Extraction and SS Radioimmunoassay
For SSLI measurements, the frontoparietal cortex was rapidly
homogenized in 1 ml of 2M acetic acid using a Brinkman polytron
(setting 5, 30 s). The extracts were boiled for 5 min in a water bath,
chilled in ice, and aliquots (100 ml) were removed for protein
determination (46). The homogenates were subsequently centri-
fuged at 15,000 3 g for 15 min at 4°C and the supernatant was
neutralized with 2 M NaOH. The extracts were then stored at
270°C until assay. The SSLI content was determined in tissue
extracts by a modified radioimmunoassay method (46), with a
sensitivity limit of 10 pg/ml. Incubation tubes prepared in dupli-
cate contained 100 ml samples of unknown or standard solutions of
0-500 pg cyclic SS tetradecapeptide diluted in phosphate buffer
(0.05 M, pH 7.2 containing 0.3% BSA, 0.01 M EDTA), 200 ml of
appropriately diluted anti-SS serum, 100 ml of freshly prepared
125I-Tyr11-SS diluted in buffer to give 6,000 cpm/assay tube
(equivalent to 5–10 pg), and enough buffer to give a final volume
of 0.8 ml. All reagents as well as the assay tubes were kept chilled
in ice before their incubation for 48 h at 4°C. Separation of bound
and free hormone was accomplished by the addition of 1 ml
dextran-coated charcoal (dextran T-70: 0.2% w/v, Pharmacia,
Uppsala, Sweden; charcoal Norit A: 2% w/v, Serva, Feinbio-
chemica, Heidelberg, Germany). Serial dilution curves for the
samples were parallel to the standard curve. The intra- and inter-
assay variation coefficients were 6.2 and 8.6%, respectively.
Binding Assay
Tyr11-SS was radioiodinated by the chloramine-T method (30).
The tracer was purified in a Sephadex G-25 fine column (1 3 100
cm) which had been equilibrated with 0.1 M acetic acid containing
BSA 0.1% (w/v). The specific activity of the purified labelled
peptide was determined by the method of Singh et al. (57) and was
approximately 600 Ci/mmol.
Membranes from rat frontoparietal cortex were prepared as
previously described by Reubi (51). Membrane protein was deter-
mined by the method of Lowry (36) using BSA as a standard.
Specific SS binding was measured according to the method of
Czernik and Petrack (16) modified from Srikant and Patel (58).
Briefly, brain membranes (0.15 mg protein/ml) were incubated in
250 ml of a medium containing 50 mM Tris-HCl buffer (pH 7.5),
5 mM MgCl2, 0.2% (w/v) BSA and 0.1 mg/ml bacitracin with 250
pM 125I-Tyr11-SS either in the absence or presence of 0.01-10 nM
unlabelled SS. After incubation for 60 min at 30°C, the free
radioligand was separated from the bound radioligand by centrif-
ugation at 11,000 3 g for 2 min and the resultant pellet was
counted in a Kontron gamma counter. Nonspecific binding was
obtained from the amount of radioactivity bound in the presence of
1027 M unlabelled SS and represented about 20% of the binding
TABLE 1
EFFECT OF 2-PYRIDYLETHYLAMINE (PEA), MEPYRAMINE AND
MEPYRAMINE PLUS PEA ON SOMATOSTATIN-LIKE
IMMUNOREACTIVE (SSLI) CONTENT AND EQUILIBRIUM
PARAMETERS FOR SOMATOSTATIN (SS) BINDING IN RAT
FRONTOPARIETAL CORTEX
Groups
SS receptors
Bmax Kd SSLI
Control 409 6 30 0.27 6 0.02 9.15 6 0.73
PEA
2.5 mg/rat 489 6 18* 0.33 6 0.03
5.0 mg/rat 523 6 13** 0.37 6 0.04*
10.0 mg/rat 603 6 24** 0.42 6 0.04** 7.84 6 1.64
20.0 mg/rat 631 6 27** 0.46 6 0.05**
Control 407 6 26 0.28 6 0.03 11.92 6 0.99
Mepyramine
5 mg/Kg 392 6 16 0.25 6 0.02
10 mg/Kg 395 6 14 0.24 6 0.02
30 mg/Kg 401 6 19 0.24 6 0.03 10.79 6 0.84
60 mg/Kg 398 6 20 0.25 6 0.02
Control 407 6 26 0.28 6 0.03 10.72 6 1.40
Mepyramine plus PEA 381 6 15 0.33 6 0.03 10.38 6 0.70
Binding parameters were calculated from Scatchard plots by linear
regression. Units for SSLI are ng of SS per mg of protein, units for Kd are
nM and units for Bmax are femtomoles of SS bound per mg of protein. The
results are the means 6 SEM of five separate experiments performed in
duplicate. Statistical comparison versus control: * p , 0.05; ** p , 0.01.
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observed in the absence of unlabelled peptide. This non-specific
component was subtracted from the total bound radioactivity in
order to obtain the corresponding specific binding.
Evaluation of Radiolabelled Peptide Degradation
To determine the extent of tracer degradation during incuba-
tion, we measured the ability of preincubated peptide to bind to
fresh membranes as previously described (1). Briefly, 125I-
Tyr11-SS (250 pM) was incubated with membranes from rat fron-
toparietal cortex (0.15 mg protein/ml) for 60 min at 30°C. After
this preincubation, aliquots of the medium were added to fresh
membranes and incubated for an additional 60 min at 30°C. The
fraction of the added radiolabelled peptide which was specifically
bound during the second incubation was measured and expressed
as a percentage of the binding that had been obtained in control
experiments performed in the absence of membranes during the
preincubation period.
Adenylyl Cyclase Assay
AC activity was measured as previously reported (31) with
minor modifications. Briefly, rat frontoparietal cortical membranes
(0.06 mg/ml) were incubated with 1.5 mM ATP, 5 mM MgSO4, 10
mm GTP, an ATP-regenerating system (7.5 mg/ml creatin phos-
phate and 1 mg/ml creatine kinase), 1 mM IBMX, 0.1 mM PMSF,
1 mg/ml bacitracin, 1 mM EDTA, and test substances (1024 M SS
or 1025 M FK) in 0.1 ml of 0.025 M triethanolamine/HCl buffer
(pH 7.4). After a 15 min incubation at 30°C, the reaction was
stopped by heating the mixture for 3 min. After cooling, 0,2 ml of
an alumina slurry (0.75 g/ml in triethanolamine/HCl buffer, pH
7.4) was added and the suspension centrifuged. The supernatant
was taken for assay of cyclic AMP by the method of Gilman (28).
The concentration of SS used was that necessary to achieve inhi-
bition of rat (55) and human (5,27) brain AC. FK was used at a
concentration that could effectively stimulate the AC catalytic
subunit of rat brain (55).
Data Analysis
The computer program LIGAND (39) was used to analyse the
binding data. The use of this program enabled models of receptors
that best fit the given sets of data to be selected. The same program
was also used to present the data in the form of Scatchard plots
(53) and to compute values for the receptor affinity (Kd) and
density (Bmax) that best fit the sets of binding data for each rat.
Statistical comparisons of all the data were carried out with one
way analysis of variance (ANOVA) and significant differences
between experimental groups were evaluated by Student’s New-
man-Keuls multiple comparison procedures. Means among groups
FIG. 1. Effect of 2-pyridylethylamine (PEA) (10 mg/rat, i.c.v.) on somatostatin (SS) binding to rat frontoparietal cortical membranes. Left panel:
Competitive inhibition of specific 125I-Tyr11-SS binding by unlabelled SS to frontoparietal cortical membranes. Membranes (0.15 mg protein/ml)
were incubated for 60 min at 30°C in the presence of 250 pM 125I-Tyr11-SS and increasing concentrations of native peptide. Points correspond to
values for the animals in the control group (v) and PEA-treated group (V). Each point is the mean 6 SEM of five replicate experiments. Right panel:
Scatchard analysis of the binding data.
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were considered significantly different when the P value was less
than 0.05. Each individual experiment was performed in duplicate.
RESULTS
The administration of PEA or mepyramine did not affect SSLI
content in the rat frontoparietal cortex as compared with the
control group (Table 1).
The specific binding of 125I-Tyr11-SS to frontoparietal cortical
membranes was time-dependent in all the experimental groups; an
apparent equilibrium was reached and maintained between 50–180
min at 30°C (data not shown). All subsequent binding experiments
were therefore conducted at 30°C for 60 min. The specific binding
of 125I-Tyr11-SS to rat frontoparietal cortical membranes was
significantly increased in PEA-treated rats at a dose of 2.5, 5, 10 or
20 mg/rat as compared to control conditions (Fig. 1, left panel).
This increase is due to an increase in the maximal number of SS
receptors and dissociation constant, as revealed by Scatchard plots
of the binding data (Fig. 1, right panel; Table 1). Subsequent
studies were carried out with the dose of 10 mg/rat, the dose
frequently used by other investigators (11). The addition of 1025
M PEA to the incubation medium changed neither the number nor
the affinity of the SS receptors in the membranes of normal rats
(data not shown). The stability of the radioligand in membranes
from different groups was measured to examine the possibility that
decreased 125I-Tyr11-SS degradation might account for increased
SS binding by these membranes. SS inactivation by plasma mem-
branes after a 60 min incubation at 30°C was similar (8–10%) in
all experimental groups. The administration of mepyramine at a
dose of 5, 10, 30 or 60 mg/kg had no observable effect on SS
binding. Subsequent studies were carried out with 10 mg/kg, the
dose frequently used by other investigators (42). Pretreatment with
the H1-receptor antagonist mepyramine abolished the PEA-in-
duced changes in SS binding (Fig. 2, Table 1).
In a previous study carried out by our laboratory, inhibition of
basal and FK-stimulated AC activity in frontoparietal cortical
membranes from control rats was observed at a concentration of
1024 M SS, with no significant inhibition at lower doses (50). In
the present study, additional experiments have been carried out to
study the effect of a higher dose of SS on inhibition of AC activity
in order to determine if 1024 M is a maximal concentration. In this
regard, the SS-mediated inhibition of AC observed at 1023 M SS
was the same as that observed at 1024 M. Therefore, all subse-
quent experiments on SS-mediated inhibition of AC activity were
carried out with 1024 M SS. The functional coupling of the SS
receptors to the AC system was studied in frontoparietal cortical
membranes from control, PEA-, mepyramine- and mepyramine
plus PEA-treated rats. No significant differences were seen for
either the basal or FK-stimulated AC enzyme activities in any of
FIG. 2. Effect of mepyramine plus 2-pyridylethylamine (PEA) on somatostatin (SS) binding to rat frontoparietal cortical membranes. Mepyramine (30
mg/kg, IP) was administered 1 h before PEA (10 mg/rat, i.c.v.). Left panel: Competitive inhibition of specific 125I-Tyr11-SS binding by unlabelled SS
to frontoparietal cortical membranes. Membranes (0.15 mg protein/ml) were incubated for 60 min at 30°C in the presence of 250 pM 125I-Tyr11-SS
and increasing concentrations of native peptide. Points correspond to values for the animals in the control group (v) and mepyramine plus PEA-treated
group (V). Each point is the mean 6 SEM of five replicate experiments. Right panel: Scatchard analysis of the binding data.
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the experimental groups (Table 2). In frontoparietal cortical mem-
branes from all the experimental groups studied, SS (1024 M)
inhibited the basal and FK-stimulated AC activities (Table 2),
which is in agreement with other authors (37,55). In the PEA
group, however, the capacity of SS to inhibit basal and FK-
stimulated AC activity in the frontoparietal cortex was signifi-
cantly higher than in the control group (Table 2).
The stable GTP analogue 59-guanylylimidodiphosphate [Gp-
p(NH)p] was employed to evaluate if there were changes in the
functional activity of Gi proteins which might explain the greater
SS-mediated inhibition of AC activity observed in the present
study. Low concentrations of Gpp(NH)p inhibited FK (3 3 1026
M)-stimulated AC activity in frontoparietal cortical membranes
from control and PEA-treated rats, with a maximum inhibition
being observed at a concentration of 1027 M (Fig. 3). This inhib-
itory effect has been used by several authors as a measure of Gi
functional activity (61,68). No significant differences in Gp-
p(NH)p-mediated inhibition of AC activity were observed between
the control and PEA-treated animals (Fig. 3).
Pretreatment with the H1-receptor antagonist mepyramine pre-
vented the PEA-induced changes in SS-mediated inhibition of AC
activity (Table 2) whereas mepyramine alone had no observable
effect on these parameters (Table 2).
DISCUSSION
This study is the first demonstration that a H1-histaminergic
agonist induces an increase in the number of SS receptors, which
is associated with an increase in SS-mediated inhibition of AC
activity in the rat frontoparietal cortex.
No changes in SSLI content were detected after PEA or
mepyramine administration. These results are in good agreement
with a study of De los Frailes et al. (20) who observed that
histamine caused no significant differences in either SS release or
SS intracellular content in rat fetal cerebral cortical cells in culture.
H1-histaminergic receptors seem to mediate the action of PEA
on the somatostatinergic system since the changes in the SS
receptor/effector system induced by this agonist were prevented by
pretreatment with the H1-receptor antagonist mepyramine. More-
over, the addition of PEA or mepyramine in vitro to frontoparietal
cortical membranes obtained from untreated rats did not affect the
SS binding parameters.
The SSLI content and equilibrium parameters of the SS recep-
tors in the frontoparietal cortex of control rats were similar to those
previously reported by others (48,58). To date, five different SS
receptor subtypes have been cloned (4,32), all of which appear to
be expressed in the rat cerebral cortex, as demonstrated by a study
of the tissue distribution of the messenger ribonucleic acid
(7,32,47). The fact that this study with 125I-Tyr11-SS shows linear
Scatchard plots indicates that all the SS receptor subtypes have
similar high affinity for the radioligand used.
The rapid changes in SS binding observed after PEA adminis-
tration are in keeping with the modifications in this neuropeptide
which were provoked by TRH (56) or cysteamine (59). In addition,
Bruno et al. (8) observed a rapid increase in SS receptor mRNA as
soon as 2 h following agonist treatment in GH3 cells. Thus, the
increase in SS binding observed after PEA administration may be
due to synthesis of some SS receptors from existing or newly
transcribed mRNA.
We previously demonstrated that an acute i.c.v. administration
of histamine increases the SS receptor-effector system in the
Wistar rat frontoparietal cortex (50). The present findings, there-
fore, suggest that the H1-histaminergic system is involved, at least
in part, in this histamine-induced modulation of the somatostatin-
ergic system.
It is now well established that histamine stimulates phospho-
inositide breakdown in rat and guinea-pig brain slices through
activation of H1-receptors (2,6,14,18). Therefore, it is tempting to
speculate that phosphoinositide hydrolysis induced by H1 agonists
may cause changes in the overall conformation of the cell mem-
brane which may induce the exposure of a pool of presynthesized
SS receptors secuestered within the plasma membrane.
The data reported here show that frontoparietal cortical SS
receptors are coupled in an inhibitory fashion to AC. The inhibi-
tion was already present in basal conditions, which is in agreement
with previous reports (5,27,55). A relatively high concentration of
SS was required to produce inhibition of AC, although the same
concentration has been shown by other authors to be necessary for
SS-mediated inhibition of rat (55) and human brain (5,27) AC
activity. Several lines of evidence, however, indicate that the
inhibition of AC activity achieved by 1024 M SS is not a nonspe-
cific effect but rather is mediated by SS receptors. In this regard,
the GTP dependence of the inhibitory effect suggests the involve-
ment of a G protein in the response. This finding is consistent with
binding studies on postmortem human and rat brain tissue which
have shown that the binding of SS to its recognition site is affected
TABLE 2
EFFECT OF SOMATOSTATIN (SS) (1024M) AND FORSKOLIN (FK) (1025 M) ON BRAIN ADENYLYL CYCLASE (AC) ACTIVITY (PMOL CAMP/MIN/
MG PROTEIN) IN FRONTOPARIETAL CORTEX MEMBRANES FROM CONTROL (n 5 15), 2-PYRIDYLETHYLAMINE (PEA) (n 5 5)-, MEPYRAMINE
(n 5 5)- AND MEPYRAMINE PLUS PEA- (n 5 5)-TREATED RATS.
PEA Mepyramine 1 PEA Mepyramine
Control Treated Control Treated Control Treated
Basal activity 174 6 8 154 6 6 160 6 4 153 6 5 165 6 4 159 6 3
11024M SS 130 6 8 105 6 4* 124 6 3 114 6 3 131 6 5 121 6 3
%SS inhibition of basal activity 25 6 2 32 6 1* 23 6 2 25 6 3 21 6 3 24 6 2
11025M FK 1065 6 44 1051 6 24 956 6 41 933 6 35 921 6 38 827 6 10
Fold FK stimulation over basal 6.1 6 0.2 6.8 6 0.3 6.0 6 0.3 6.1 6 0.4 5.6 6 0.2 5.2 6 0.2
1025M FK 1 1024M SS 850 6 59 695 6 18* 740 6 27 720 6 26 658 6 17 644 6 31
%SS inhibition of FK stimulation 20 6 2 34 6 1*** 22 6 2 23 6 1 26 6 3 22 6 4
Experiments were performed as described in Methods. Values represent the mean 6 S.E.M. of the determinations performed. Statistical comparison
versus control: *p , 0.05, ***p , 0.001.
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by GTP in a manner consistent with the involvement of a G protein
(27).
It has been shown that SS inhibits basal AC activity in neuronal
but not glial cells, and in membranes from the cerebral cortex,
striatum and mesencephalic regions of mouse embryos
(12,13,15,66). In a fresh astrocyte-rich suspension from the rat
cerebral cortex, vasoactive intestinal peptide (VIP), an agonist
acting through Gs, was observed to stimulate cAMP accumulation
up to 2.3 times the basal levels whereas SS did not inhibit this
effect at any of the VIP concentrations (15). Due to the differential
response of neuronal and glial cells to AC inhibition by SS, it is
possible that the cell heterogeneity of the present preparations may
be the cause of the high SS concentration necessary to obtain
inhibition of AC, both by our group and by other authors. In
addition, the synaptic concentration of SS is, to date, unknown. On
the other hand, glial SS receptors have a lower affinity for the
peptide than neurons (15).
The ability of SS to inhibit basal and FK-stimulated AC was
increased in frontoparietal cortical membranes from PEA-treated rats
as compared with the control values. No significant differences were
observed, however, between the PEA-treated and control groups for
either basal or FK-stimulated AC activity in the frontoparietal cortex.
This result suggests that the integrity of at least the catalytic subunit
of the enzyme is intact in the PEA-treated group.
The functional activity of Gi proteins was measured in control
and PEA-treated rats in order to determine if the greater inhibition
of AC by SS observed in the PEA group was due to a change at
this level. In both control and PEA-treated rats, the nonhydrolyz-
able GTP analogue Gpp(NH)p elicited a characteristic biphasic
effect on FK-stimulated AC activity, with low concentrations
inhibiting FK-stimulated AC activity and high concentrations
stimulating it. This biphasic effect is due to the activation of Gi and
Gs proteins, respectively, due to the higher affinity of Gi proteins
for Gpp(NH)p (61). The lack of changes in the inhibitory effect of
Gpp(NH)p on FK-stimulated AC activity in cortical membranes
from PEA-treated rats suggests that the increased SS inhibition of
AC activity is not a result of an increase in Gi protein-AC coupling
but is most likely related to the observed increase in the number of
SS receptors.
The significance of these results is, at present, difficult to
assess. Since a significant decrease in histamine content (38) and
SS content and receptors (3) has been described in certain neuro-
psychiatric disorders such as Alzheimer’s disease, the present
findings could be of interest in understanding the pathophysiology
of such disorders.
In summary, the present study reveals the existence of in vivo
interactions between the H1-histaminergic and the somatostatiner-
gic systems in the rat frontoparietal cortex. Since SS and histamine
modulate higher nervous activity (19,26,43), behavioral arousal
(17,33,64) and seizure susceptibility (35,48,54) in a similar man-
ner, the increase in the number of SS receptors may reflect a
positive feedback mechanism further enhancing the modulatory
effects of SS on histaminergic neurotransmission. Since the H1
antagonist mepyramine had no effect on the measured parameters,
it is tempting to speculate that endogenous histamine might have a
phasic influence on SS receptors rather than a tonic effect.
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